Intrathecal pain management with ziconotide: Time for consensus?
Abstract This article summarizes recommendations made by six pain specialists who discussed the rationale for ziconotide intrathecal analgesia (ITA) and the requirement for evidence‐based guidance on its use, from a European perspective. Riemser Pharma GmbH (Greifswald, Germany), which holds the Eur...
Main Authors: | Georgios Matis, Pasquale De Negri, Denis Dupoiron, Rudolf Likar, Xander Zuidema, Dirk Rasche |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.2055 |
Similar Items
-
A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review
by: Emanuele Rubiu, et al.
Published: (2024-03-01) -
Lumbar neuropathic pain of lower limbs treated by spinal infusion of ziconotide a case – report
by: Luca Quadrino
Published: (2008-09-01) -
Serious pain treatment with intrathecal ziconotide pathway - clinical case
by: Giovanni Nicotera, et al.
Published: (2008-04-01) -
Intrathecal pain management: a team-based approach
by: Adler JA, et al.
Published: (2017-11-01) -
Intracisternal ziconotide infusion. Clinical case of an inoperable pharynx cancer patient with severe cervico-facial pain syndrome
by: Sergio Mameli, et al.
Published: (2015-03-01)